Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

SDX-105

Trial Locations (17)

14642

University of Rochester Medical Center, Rochester

20007

Georgetown University Medical Center - Lombardi Cancer Center, Washington D.C.

22908

University of Virginia Medical Center, Charlottesville

37203

The Sarah Cannon Cancer Center, Nashville

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

77030

MD Anderson Cancer Center, Houston

78705

Southwest Regional Cancer Center, Austin

83712

Mountain States Tumor Institute, Boise

92083

San Diego Cancer Center, Vista

92262

Comprehensive Cancer Center-Desert Regional Medical Center, Palm Springs

35294-3300

University of Alabama at Birmingham, Birmingham

02115

Dana Farber Cancer Institute, Boston

08901

The Cancer Institute of New Jersey, New Brunswick

B3H 2Y9

Queen Elizabeth Health Sciences Centre, Halifax

K1H 8L6

The Ottawa Hospital - General Campus, Ottawa

M4N 3M5

Toronto Sunnybrook Regional Cancer Centre, Toronto

G1J 1Z4

CHA Hopital Enfant-Jesus, Québec

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Cephalon

INDUSTRY